Introduction Introduction
Tenofovir Disoproxil Fumarate-emtricitabine (TDF-FTC; Truvada ; Gilead Sciences) as a daily fxed dose tablet ® is approved by the Food and Drug Administration for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition for persons with increased risk for HIV infection. TDF has well-described toxicities, including greater loss of bone mineral density (BMD) after antiretroviral therapy (ART) initiation and increased risk of fragility fracture.
Daily use of TDF-FTC as PrEP is associated with signifcant reduction in BMD, although to a lesser degree than that seen during initial treatment for HIV.
Hence, long-term PrEP use is potentially associated with increased fracture risk. Glidden and colleagues showed that mean BMD returns to baseline levels within 12-18 months after discontinuation of TDF-based PrEP. However, the effects of continued long-term exposure to TDF during PrEP on bone are not known.
The mechanism by which TDF induces BMD loss is unclear, but it appears to be associated with an increase in parathyroid hormone (PTH) levels and PTH-controlled calcium and phosphate metabolism. Some data suggest that TDF induces a state of functional vitamin D defciency. Strategies to attenuate or prevent BMD loss when TDF-containing PrEP is given for prolonged periods of time are needed. Overton et al. reported a marked reduction in the degree of BMD loss during initial therapy of HIV infection with vitamin D3 4,000 IU/day and calcium supplementation. When vitamin D-calcium was coadministered with efavirenz plus TDF-FTCbased ART for 48 weeks, the amount of BMD loss at the hip measured by dual-energy X-ray absorptiometry (DEXA) was approximately half that seen with placebo (−1.5% vs. −3.2%, respectively; p < .001).
The objective of our study was to evaluate if supplementation with vitamin D will favorably affect the adverse changes in bone turnover markers (BTM) that occur after initiation of PrEP with TDF-FTC. Our primary hypothesis was that supplementation with vitamin D 4,000 IU/day will signifcantly blunt the increase in the BTM procollagen-I N-terminal propeptide (P1NP) that occurs after initiation of PrEP with TDF-FTC. Secondary hypotheses included that supplementation with vitamin D 4,000 IU/day will signifcantly blunt the increases in BTM C-telopeptide (CTX) and PTH that occur after initiation of PrEP with TDF-FTC and increase levels of 25-OH vitamin D3 compared with control participants not receiving supplementation.
Materials and Methods Materials and Methods

Study design Study design
This was a nonrandomized prospective interventional study with retrospectively matched concurrent controls clinical trial and were enrolled concurrently into the parent trial. Participation in the substudy was not required for continued participation in the CCTG 595 trial. The intervention included 48 men matched 1:1 with concurrent controls based on age (±5 years), race (black vs. nonblack), and body mass index (BMI; ±3 kg/m ).
The intervention group and controls were also matched based on season of enrollment to minimize the effect of sun exposure on baseline vitamin D levels.
Participants Participants
Study participants were drawn from the men or transgender women at high risk of acquiring HIV infection who received daily PrEP with TDF-FTC aged 18 years or older. All study participants were naive to TDF-FTC at the baseline visit. Participant enrollment to the substudy occurred at the 24-week visit of the CCTG 595 trial. 
Treatment Treatment
Vitamin D3 was supplied as 2,000 IU capsules (NatureMade, Mission Hills, CA) taken as two capsules once daily, taken from week 24 to week 48. In this study, supplemental calcium was not used because in ACTG 5280 dietary calcium intake among untreated HIV-infected participants was generally adequate. We thus anticipated that the largely healthy HIV-uninfected participants in this study would also have adequate dietary calcium intake.
Clinical and laboratory evaluations Clinical and laboratory evaluations
Plasma from participants was collected and stored at entry, 24, and 48 weeks. BTMs were measured after completion of the study on stored samples. PTH, CTX-1, and P1NP were measured using ELISA-based kits (Reddot Biotech, Inc., BC, Canada and MyBiosource, Inc., San Diego, CA), respectively. All samples were analyzed according to manufacturer's recommended procedures, where the replicates were all within acceptable percentage of coebcient of variation criteria set a priori at <15%. The concentration of 25-OH vitamin D3 was determined using a validated liquid chromatography-mass spectrometry method. Bone density measurements were not performed.
To calculate the average daily dietary intake of vitamin D and calcium from food, participants were asked to recall food items eaten over the last 3 days at the week 36 visit. A calculator adapted from the USDA database was used to quantify vitamin D and calcium intake. Tenofovir diphosphate in dried blood spots (DBS) served as an objective measure of adherence to PrEP. 
Statistical analysis Statistical analysis
Forty-four pairs of cases and controls provides 80% power to detect a difference of 20% in the weeks 24-48 change in P1NP between the intervention group and controls, assuming the standard deviation of change is 40% using a paired t-test with a two-sided alpha = 0.05. 
Results Results
Forty-eight participants were enrolled to the vitamin D supplementation (intervention) group and compared with 48 matched controls. Baseline characteristics of the groups were similar with regard to age, race, and BMI (Table 1 ). All participants were MSM. The number of Hispanic participants was higher in the vitamin D group than in the control group (33% vs. 17%). Both at baseline and week 24, most study participants had subcient vitamin D levels (≥ 20 ng/mL; Values are given as n (%).
P1NP level was unexpectedly higher among the intervention group than controls at week 24 (Table 3) . P1NP
decreased by a mean of −27.6 ± 49.9 pg/mL from week 24 to 48 with vitamin D supplementation. The P1NP level decreased only −2.5 ± 40.2 pg/mL in controls (Table 3 and Fig. 1 ). The mean change in P1NP from week 24 to week 48 between groups was signifcantly different (p = .011). The percent reduction in P1NP level from week 24 to 48 was also greater with vitamin D supplementation (−14.6% ± 52.5%) than in controls (20.7% ± 67.3%, p = .006). In a multivariable linear regression model controlling for week 24 P1NP levels, greater increase in 25-OH vitamin D3 between weeks 24 and 48 was associated with greater decrease in P1NP between weeks 24 and 48 (coebcient estimate = −0.59, p = .006). Post hoc mixed model analysis of the absolute change in P1NP from week 24 to 48 showed no statistically signifcant difference between the groups after adjusting for the week 24 P1NP levels (p = .23). P1NP, procollagen-I N-terminal propeptide; CTX, C-telopeptide; IQR, interquartile range.
FIG. 1. Change in P1NP level
There was no signifcant change in P1NP, CTX, PTH, or 25-OH vitamin D3 levels from baseline to week 24 (Tables 3 and 4) . Levels of 25-OH vitamin D3 increased from week 24 to 48 among the intervention group receiving 4,000 IU of vitamin D3 daily, but this was not statistically signifcant (within-group p = .065). The change in P1NP levels observed from baseline to week 24 did not differ by adherence to PrEP assessed at week 12 (data not shown). Controls 108.4 ± 210.5 −0.9 ± 13.7
Paired t-test was used.
PTH, parathyroid hormone.
Discussion Discussion
Contrary to our expectations, there were no changes in BTMs or levels of PTH over the initial 24 weeks of PrEP with daily TDF-FTC and a high degree of adherence assessed by DBS TDF-DP levels. However, supporting our primary hypothesis, the addition of 4,000 IU/day of vitamin D3 at week 24 to week 48 of PrEP resulted in a signifcant decrease in P1NP levels compared with unsupplemented controls taking ≤400 IU/day. This suggests that vitamin D supplementation has the potential to blunt the decreases in BMD associated with daily TDF-FTC PrEP.
The fxed-dose combination of TDF-FTC has proven to be a highly effective PrEP agent. Because PrEP involves long-term administration of drugs to generally healthy individuals, it is particularly important to monitor drug safety. The mechanism by which TDF induces BMD loss is unclear. free 1,25-OH(2)D levels in individuals with higher plasma tenofovir concentrations, which may explain TDFassociated increased PTH levels. A recent study reported that PTH-vitamin D-fbroblast growth factor 23 (FGF23), which causes phosphate wasting, is a primary contributor to TDF-associated decrease in BMD.
Moreover, the level of vitamin D binding protein has been shown to increase upon initiation of TDF-based therapy, which may be associated with bone loss. Thus, when TDF-containing PrEP is used for prolonged P1NP at week 48 correlated with the percentage change in total hip BMD (r = −0.32, p = .01) and the change in lumbar spine BMD (r = −0.37, p = .002) (Overton ET, unpublished data). Measurement of circulating BTMs can be confounded by within-patient and biologic variability (age, gender, BMI, and circadian variation). In this study however, we matched for age and BMI, and all were male at birth.
Adherence to vitamin D in this study was high by self report, and measured adherence to PrEP was also high and unaffected by the daily use of vitamin D. However, we observed only a nonsignifcant trend toward increased 25-OH vitamin D3 levels from week 24 to 48 with 4,000 IU/day, suggesting a possible contribution of unreported suboptimal adherence. A majority of our study participants had subcient vitamin D levels at baseline and at week 24, thus there may have been limited room for improvement with supplementation. Sunny southern California weather may have contributed to this phenomenon. However, additional vitamin D still has the potential to provide beneft, as was observed in patients with HIV initiating TDF-containing ART in ACTG 5280, where baseline vitamin D status did not inuuence the effect of vitamin D supplementation on BMD and this beneft occurred at all vitamin D levels. We did not observe a differential effect on P1NP levels based on baseline 25-OH vitamin D3 levels in our study.
Conclusion Conclusion
Our study demonstrated that daily PrEP with Truvada in MSM did not adversely affect the BTMs P1NP and CTX, nor did it affect levels of PTH and vitamin D over the initial 24 weeks. The addition of vitamin D3 4,000 IU/day beginning at week 24 resulted in a signifcant decrease in P1NP levels at week 48 compared with matched controls taking ≤400 IU/day. Hence, vitamin D3 4,000 IU/day in MSM taking Truvada as PrEP should be further studied as an intervention to improve bone health in this population.
